Therapy of childhood acute myelogenous leukemias

Annals of Hematology

Volumn 73, Issue 1, 1996, Pages 11-24

  Vormoor, J ^a   Boos, J ^a   Stahnke, K ^b   Jurgens H ^a   Ritter, J ^a   Creutzig, U ^a  

^a UNIVERSITY OF MÜNSTER   (Germany)

^b UNIVERSITY OF ULM   (Germany)

Author keywords

Anthracyclines; Bone marrow transplantation; Childhood acute myelogenous leukemia; Cytosine arabinoside

Indexed keywords

AMSACRINE; ANTHRACYCLINE; ASPARAGINASE; AZACITIDINE; CARMUSTINE; CYCLOPHOSPHAMIDE; CYTARABINE; DAUNORUBICIN; DOXORUBICIN; ETOPOSIDE; MERCAPTOPURINE; METHOTREXATE; METHYLPREDNISOLONE; MITOXANTRONE; PREDNISONE; RETINOIC ACID; TIOGUANINE; VINCRISTINE;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; BONE MARROW TRANSPLANTATION; CANCER RADIOTHERAPY; CANCER REGRESSION; CANCER SURVIVAL; CHILDHOOD LEUKEMIA; HUMAN; INTRATHECAL DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION; SURVIVAL RATE;

ANTINEOPLASTIC AGENTS; BONE MARROW TRANSPLANTATION; CENTRAL NERVOUS SYSTEM NEOPLASMS; CHILD; CHILD, PRESCHOOL; CLINICAL TRIALS; HUMANS; INFANT; LEUKEMIA, MYELOCYTIC, ACUTE; PROGNOSIS;

EID: 0030035716     PISSN: 09395555     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002770050193     Document Type: Article

References (131)

1. Amadori S, Testi AM, Arico M, Cormelli A, Giuliano M, Madon E, Masera G, Rondelli R, Zanesco L, Mandelli F (1993) Prospective comparative study of bone marrow transplantation and postremission chemotherapy for childhood acute myelogenous leukemia. J Clin Oncol 11:1046-1054
2. Appelbaum FR, Fisher LD, Thomas DE (1988) Chemotherapy v marrow transplantation for adults with acute nonlymphocytic leukemia: a five-year follow-up. Blood 72:179-184
3. Arlin Z, Case DC, Moore J, Wiernik P, Feldman E, Saletan S, Desai P, Sia L, Cartwright K (1990) Randomized multicenter trial of cytosine arabinoside with mitoxantrone or daunorubicin in previously untreated adult patients with acute nonlymphocytic leukemia (ANLL). Leukemia 4:177-183
4. Avvisati G, Mandelli F, Petti MC, Vegna ML, Spadea A, Liso V, Specchia A, Bernasconi C, Alessandrino EP, Piatti C, Carella AM (1990) Idarubicin (4-demethoxydaunorubicin) as single agent for remission induction of previously untreated acute promyelocytic leukemia: a pilot study of the Italian cooperative group GIMEMA. Eur J Haematol 44:257-260
5. Ball ED, Rybka WB (1993) Autologous bone marrow transplantation for adult acute leukemia. Hematol Oncol Clin North Am 7:201-231
6. Behar C, Bertrand Y, Rubie H, Vilmer E, Babin A, Brock P, Boutard P, Solbu G, Suciu S, Robert A (1992) Mitoxantrone and high dose ARA-C for the treatment of ANLL in childhood: a pilot study of the EORTC CLCG (EORTC 58 872). Leukemia 6 [Suppl 2]:63-65
7. Berman E, Heller G, Santorsa J, McKenzie S, Gee T, Kempin S, Gulati S, Andreeff M, Kolitz J, Gabrilove J, Reich L, Mayer K, Keefe D, Trainor K, Schluger A, Penenberg D, Raymond V, O'Reilly R, Jhanwar S, Young C, Clarkson B (1991) Results of a randomized trial comparing idarubicin and cytosine arabinoside with daunorubicin and cytosine arabinoside in adult patients with newly diagnosed acute myelogenous leukemia. Blood 77:1666-1674
8. Bielack S, Erttmann R, Winkler K, Landbeck G (1989) Doxorubicin: effect of different schedules on toxicity and antitumor efficacy. Eur J Cancer Clin Oncol 25:873-882
9. Biondi A, Rovelli A, Cantu-Rajnoldi A, Fenu S, Basso G, Luciano A, Rondelli R, Mandelli F, Masera G. Testi AM (1994) Acute promyelocytic leukemia in children: experience of the Italian Pediatric Hematology and Oncology Group (AIEOP). Leukemia 8:1264-1268
10. Bishop JF, Lowenthal RM, Joshua D, Matthews JP, Todd D, Cobcroft R, Whiteside MG, Kronenberg H, Ma D, Dodds A, Herrmann R, Szer J, Wolf MM, Young G (1990) Etoposide in acute nonlymphocytic leukemia. Blood 75:27-32
11. Bloomfield CD (1985) Postremission therapy in acute myeloid leukemia. J Clin Oncol 3:1570-1572
12. Bloomfield CD, Lawrence D, Arthur DC, Berg DT, Schiffer CA, Mayer RJ (1994) Curative impact of intensification with high-dose cytarabine (HiDAC) in acute myeloid leukemia (AML) varies by cytogenetic group. Blood 84 [Suppl 1]:111a
13. Bonetti F, Montagna D, Porta F, Lanfranchi A, Zecca M, Comoli P, Personeni A, Gritti G, Maccario R, DeStefano P, Locatelli F (1995) Autologous bone marrow transplantation for acute myeloid leukaemia in children using total body irradiation and melphalan as conditioning regimen. Leukemia 9:570-575
14. Boos J, Krümpelmann S, Schulze-Westhoff P, Euting T, Berthold F, Jürgens H (1996) Steady state levels and bone marrow toxicity of etoposide in children and infants: does etoposide require age dependent dose calculation. Med Pediatr Oncol (in press)
15. Brenner MK, Rill DR, Moen RC, Krance RA, Heslop HE, Mirro J, Anderson FW, Ihle JN (1994) Gene marking and autologous bone marrow transplantation. Ann N Y Acad Sci 716:204-215
16. Büchner T, Urbanitz D, Emmerich B, Fischer JT, Fülle H-H, Heinecke A, Hossfeld DK, Koeppen KM, Labedzki L, Löffler H, Nowrousian MR, Pfreundschuh M, Pralle H, RühI H, Wendt F-C (1982) Multicentre study on intensified remission induction therapy for acute myeloid leukemia. Leuk Res 6:827-831
17. Büchner T, Urbanitz D, Hiddemann W, Rühl H, Ludwig WD, Fischer J, Aul HC, Vaupel HA, Kuse R, Zeile G, Nowrousian MR, König HJ, Walter M, Wendt FC, Sodomann H, Hossfeld DK, Paleske Av, Löffler H, Gassmann W, Hellriegel K-P, Fülle HH, Lunscken C, Emmerich B, Pralle H, Pees HW, Pfreundschuh M, Bartels H, Koeppen KM, Schwerdtfeger R, Donhuijsen-Ant R, Mainzer K, Bonfert B, Köppler H, Zuborn K-H, Ranft K, Thiel E, Heinecke A (1985) Intensified induction and consolidation with or without maintenance chemotherapy for acute myeloid leukemia (AML): two multicenter studies of the German AML Cooperative Group. J Clin Oncol 3:1583-1589
18. Büchner T, Hiddemann W, Löffler G, Gassmann W, Maschmeyer G, Heit W, Hossfeld D, Weh H, Ludwig W-D, Thiel E, Nowrousian M, Aul C, Lengfelder E, Lathan B, Mainzer K, Urbanitz D, Emmerich B, Middelhoff G, Donhuijsen-Ant HR, Hellriegel H-P, Heinecke A (1991) Improved cure rate by very early intensification combined with prolonged maintenance chemotherapy in patients with acute myeloid leukemia: data from the AML Cooperative Group. Semin Hematol 28:76-79
19. Buckley JD, Lampkin BC, Nesbit ME, Bernstein ID, Feig S, Kersey JH, Piomelli S, Kim T, Hammond DG (1989) Remission induction in children with acute non-lymphocytic leukemia using cytosine arabinoside and doxorubicin or daunorubicin: a report from the Childrens Cancer Study Group. Med Ped Oncol 17:382-390
20. Burchenal JH, Murphy ML, Ellison RR, Syknb MP, Tan TC, Leone IA, Karnovsky DA, Craver LF, Dargeon HW, Rhoads CP (1953) Clinical evaluation of a new antimetabolite, 6-mercaptopurine, in the treatment of leukemia and allied diseases. Blood 8:965-999
21. Campana D, Pui C-H (1995) Detection of minimal residual disease in acute leukemia: methodologic advances and clinical significance. Blood 85:1416-1434
22. Cassileth PA, Harrington DP, Hines JD, Oken MM, Maza JJ, McGlave P, Bennet JM, O'Connell MJ (1988) Maintenance chemotherapy prolongs remission duration in adult acute nonlymphocytic leukemia. J Clin Oncol 6:583-587
23. Cassileth PA, Andersen JW, Bennett JM, Harrington DP, Hines JD, Lazarus HM, Mazza JJ, McGlave PP, O'Connell MJ, Paietta E, Wiernik P (1992) Escalating the intensity of postremission therapy improves the outcome in acute myeloid leukemia: the ECOG experience. Leukemia 6 [Suppl 2]:116-119
24. Cassileth PA, Andersen J, Lazarus HM, Colvin MO, Bennett JM, Stadtmauer EA, Kaizer H, Weiner RS, Edelstein M, Oken MM (1993) Autologous bone marrow transplant in acute myeloid leukemia in first remission. J Clin Oncol 11:314-319
25. Castaigne S, Chomienne C, Daniel MT, Ballerini P, Berger R, Fenaux P, Degos L (1990) All-trans retinoic acid as a differentiation therapy for acute promyelocytic leukemia. I. Clinical results. Blood 76:1704-1709
26. Chabner BA (1990) Cytidine analogues. In: Chabner BA, Collins JM (eds) Cancer chemotherapy: principles and practice. Lippincott, Philadelphia, pp 154-179
27. Champlin R, Gale RP (1987) Acute myelogenous leukemia: recent advances in therapy. Blood 69:1551-1562
28. Clift RA, Buckner DC, Appelbaum FR, Bearman SI, Petersen FB, Fisher LD, Anasetti C, Beatty P, Bensinger WI, Doney K, Hill RS, McDonald GB, Martin P, Sanders J, Singer J, Stewart P, Sullivan KM, Witherspoon R, Storb R, Hansen JA, Thomas DE (1990) Allogeneic marrow transplantation in patients with acute myeloid leukemia in first remission: a randomized trial of two irradiation regimens. Blood 76:1867-1871
29. Creutzig U, Ritter J, Riehm H, Langermann H-J, Henze G, Kabisch H, Niethammer D, Jürgens H, Stollmann B, Lasson U, Kaufmann U, Löffler H, Schellong G (1985) Improved treatment results in childhood acute myelogenous leukemia: a report of the German cooperative study AML-BFM-78. Blood 65:298-304
30. Creutzig U, Ritter J, Schellong G (1990) Identification of two risk groups in childhood acute myelogenous leukemia after therapy intensification in study AML-BFM-83 as compared with study AML-BFM-78. Blood 75:1932-1940
31. Creutzig U, Ritter J, Vormoor J, Eschenbach C, Dickerhoff R, Burdach S, Scheel-Walter H-G, Kühl J. Schellong G (1990) Transiente Myeloproliferation und akute myeloische Leukämie bei Säuglingen mit Morbus Down. Klin Pädiatr 202:253-257
32. Creutzig U, Bender-Götze C, Klingebiel T, Ebell W, Friedrich W, Stollmann-Gibbels B, Schmidt H, Suttorp M, Gratwohl A, Heyen P, Ritter J, Schellong G (1992) Vergleich der alleinigen Chemotherapie mit der allogenen Knochenmark-transplantation in erster Vollremission bei Kindern mit akuter myeloischer Leukämie in den Studien AML-BFM-83 und AML-BFM-87 - Matched-Pair Analyse. Klin Pädiatr 204:246-252
33. Creutzig U, Ritter J, Zimmermann M, Schellong G (1993) Does cranial irradiation reduce the risk for bone marrow relapse in acute myelogenous leukemia? Unexpected results of the childhood acute myelogenous leukemia study BFM-87. J Clin Oncol 11:279-286
34. Creutzig U, Harbott J, Sperling C, Ritter J, Zimmermann M, Löffler H, Riehm H, Schellong G, Ludwig W-D (1995) Clinical significance of surface antigen expression in children with acute myeloid leukemia: results of study AML-BFM-87. Blood 86:3097-3108
35. Creutzig U, Ritter J, Ludwig W-D, Niemeyer C, Reinisch I, Stollmann-Gibbels B, Zimmermann M, Harbott J (1995) Akute myeloische Leukämie bei Kindern mit Down-Syndrom. Klin Pädiatr 207:136-144
36. Creutzig U, Ritter J, Zimmermann M, Bender-Götze C, Schellong G (1995) Letter to the editor (Bone marrow transplantation). Lancet 346:60
37. Creutzig U, Ritter J, Vormoor J, Ludwig W-D, Niemeyer C, Reinisch I, Stollmann-Gibbels B, Zimmermann M, Harbott J (1996) Myelodysplasia and acute myelogenous leukemia in Down's syndrome. A report of 56 children of the AML- to Leukemia-BFM study group. (Submitted for publication)
38. Dahi GV, Simone JV, Hustu OH, Mason C (1978) Preventive central nervous system irradiation in children with acute nonlymphocytic leukemia. Cancer 42:2187-2192
39. Dahl GV, Kalwinsky DK, Mirro J, Look TA, Pui C-H, Murphy SB, Mason C, Ruggiero M, Schell M, Johnson LF, Thomas DE (1990) Allogeneic bone marrow transplantation in a program of intensive sequential chemotherapy for children and young adults with acute nonlymphocytic leukemia in first remission. J Clin Oncol 8:295-303
40. Degos L, Dombret H, Chomienne C, Daniel M-T, Miclea J-M, Chastang C, Castaigne S, Fenaux P (1995) All-transretinoic acid as a differentiating agent in the treatment of acute promyelocytic leukemia. Blood 85:2643-2653
41. Dillman RO, Davis RB, Green MR, Weiss RB, Gottlieb AJ, Caplan S, Kopel S, Preisler H, McIntyre RO, Schiffer C (1991) A comparative study of two different doses of cytarabine for acute myeloid leukemia: a phase-Ill trial of Cancer and Leukemia Group B. Blood 78:2520-2526
42. Dini G, Boni L, Abla O, Uderzo C, Polchi P, Locatelli F, Bartolomeo PD, Arcese W, Iori AP, Rossetti F, Rosti G, Andolina M, Paolucci P, Pession A, Lint MT, Lanino E, Locasciulli A, Bacigalupo A (1994) Allogeneic bone marrow transplantation in children with acute myelogenous leukemia in first remission. Bone Marrow Transplant 13:771-776
43. Ehninger G, Proksch B, Wanner T, Schuler U, Busch FW, Schmidt H, Schleyer E, Jaschonek K, Hiddemann W (1992) Intracellular cytosine arabinoside accumulation and cytosine arabinoside triphosphate formation in leukemic blast cells is inhibited by etoposide and teniposide. Leukemia 6:582-587
44. Feig SA, Lampkin B, Nesbit ME, Woods WG, Versteeg CM, Buckley JD, Kim T, Hammond GD (1993) Outcome of BMT during first complete remission of AML: a comparison of two sequential studies by the Childrens' Cancer Group. Bone Marrow Transplant 12:65-71
45. Finnish-Leukaemia-Group (1979) The effect of thioguanine on a combination of daunorubicin, cytarabine and prednisone in the treatment of acute leukaemia in adults. Scand J Haematol 23:124-127
46. Gale RP, Cline MJ (1977) High remission-induction rate in acute myeloid leukaemia. Lancet I:497-499
47. Gandhi V, Estey E, Keating MJ, Plunkett W (1993) Fludarabine potentiates metabolism of cytarabine in patients with acute myelogenous leukemia during therapy. J Clin Oncol 11:116-124
48. Ghaddar HM, Plunkett W, Kantarjian HM, Pierce S, Freireich EJ, Keating MJ, Estey EH (1994) Long-term results following treatment of newly diagnosed acute myelogenous leukemia with continuous-infusion high-dose cytosine arabinoside. Leukemia 8:1269-1274
49. Giorgiana G, Bozzola M, Locatelli F, Picco P, Zecca M, Cisternino M, Dallorso S, Bonetti F, Dini G, Borrone C, Regazzi MB, Stefano PD, Severi F (1995) Role of busulfan and total body irradiation on growth of prepubertal children receiving bone marrow transplantation and results of treatment with recombinant growth hormone. Blood 86:825-831
50. Giralt SA, Champlin RE (1994) Leukemia relapse after allogeneic bone marrow transplantation: a review. Blood 84:3603-3612
51. Gorin NC, Aegerter P, Auvert B, Meloni G, Goldstone AH, Burnett A, Carella A, Körbling M, Herve P, Maraninchi D, Löwenberg R, Verdonck LF, Planque MD, Hermans J, Helbig W, Porcellini A, Rizzoli V, Alesandrino EP, Franklin IM, Reiffers J, Colleselli P, Goldman JM (1990) Autologous bone marrow transplantation for acute myelocytic leukemia in first remission: a European survey of the role of marrow purging. Blood 75:1606-1614
52. Grier HE, Gelber RD, Link MP, Camitta BP, Clavell LA, Weinstein HJ (1992) Intensive sequential chemotherapy for children with acute myelogenous leukemia: VAPA, 80-035, and HI-C-Daze. Leukemia 6 [Suppl 2]:48-51
53. Gu Y, Alder H, Nakamura T, Schichman SA, Prasad R, Canaani O, Saito H, Croce CM, Canaani E (1994) Sequence analysis of the breakpoint cluster region in the ALL-1 gene involved in acute leukemia. Cancer Res 54:2327-2330
54. Haase D, Feuring-Buske M, Könemann S, Fonatsch C, Troff C, Verbeek W, Pekrun A, Hiddemann W, Wörmann B (1995) Evidence for malignant transformation in acute myeloid leukemia at the level of early hematopoietic stem cells by cytogenetic analysis of CD34+ subpopulations. Blood 86:2906-2912
55. Head D, Kopecky KJ, Weick J, Files JC, Ryan D, Foucar K, Montiel M, Bickers J, Fishleder A, Miller M, Spier C, Hanson C, Bitter M, Braziel R, Mills G, Welborn J, Williams W, Hewlett J, Willman C, Appelbaum FR (1995) Effect of aggressive daunomycin therapy on survival in acute promyelocytic leukemia. Blood 86:1717-1728
56. Hiddemann W (1991) Cytosine arabinoside in the treatment of acute myeloid leukemia: the role and place of high-dose regimens. Ann Hematol 62:119-128
57. Hiddemann W, Kreutzmann H, Straif K, Ludwig W-D, Mertelsmann R, Donhuijsen-Ant R, Lengfelder E, Arlin Z, Büchner T (1987) High-dose cytosine arabinoside and mitoxantrone: a highly effective regimen in refractory acute myeloid leukemia. Blood 69:744-749
58. Holler E, Kolb HJ, Mittermüller J, Kaul M, Ledderose G, Duell T, Seeber B, Schleuning M, Hintermeier-Knabe R, Ertl B, Kempeni J, Wilmanns W (1995) Modulation of acute graft-versus-host disease after allogeneic bone marrow transplantalion by tumor necrosis factor α (TNFα) release in the course of pretransplant conditioning: role of conditioning regimens and prophylactic application of a monoclonal antibody neutralizing human TNFα (MAK 195F). Blood 86:890-899
59. Hollingshead LM, Faulds D (1991) Idarubicin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in the chemotherapy of cancer. Drugs 42:690-719
60. Hurwitz CA, Krance R, Schell MJ, Santana VM, Brenner MK, Ribeirio R, Roberts WM, Mahmoud H, Belt J, Crom W, Shearer P, Mirro J (1992) Current strategies for treatment of acute myeloid leukemia at St Jude Children's Research Hospital. Leukemia 6 [Suppl 2]:39-43
61. Hurwitz CA, Mounce KG, Grier HE (1995) Treatment of patients with acute myelogenous leukemia: review of clinical trials of the past decade. J Pediatr Hematol Oncol 17:185-197
62. Kusec R, Laczika K, Knöbl P, Friedl J, Greinix H, Kahls P, Linkesch W, Schwarzinger I, Mitterbauer G, Purtscher B, Haas OA, Lechner K, Jaeger U (1994) AML1/ETO fusion mRNA can be detected in remission blood samples of all patients with t(8;21) acute myeloid leukemia after chemotherapy or autologous bone marrow transplantation. Leukemia 8:735-739
63. Lange B, Woods W, Lampkin B, Nesbit M, Feig S, Wells R, Lee JW, Buckley J, Hammond D (1994) Childrens' Cancer Group transplant trials for acute myeloid leukemia in children: a cross-study analysis of CCG-251, CCG-213, CCG-2861, and CCG-2891. In: Büchner T, Hiddemann W, Wörmann B, Schellong G, Ritter J (eds) Acute leukemias IV: prognostic factors. Springer-Verlag, Berlin Heidelberg New York, pp 724-731
64. Lapidot T, Sirard C, Vormoor J, Murdoch B, Hoang T, Caceres-Cortes J, Minden M, Patterson B, Caligiuri MA, Dick JE (1994) A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature 367:645-648
65. Laporte JP, Douay L, Lopez M, Labopin M, Jouet JP, Lesage S, Stachowiak J, Fouillard L, Isnard F, Noel-Walter MP, Pene F, Deloux J, Akker JVD, Grande M, Bauters F, Najman A, Gorin NC (1994) One hundred twenty-five adult patients with primary acute leukemia autografted with marrow purged by mafosfamide: a 10-year single institution experience. Blood 84:3810-3818
66. Lie SO (1989) Acute myelogenous leukaemia in children. Eur J Pediatr 148:382-388
67. Liesner RJ, Leiper AD, Hann IM, Chessels JM (1994) Late effects of intensive treatment for acute myeloid leukemia and myelodysplasia in childhood. J Clin Oncol 12:916-924
68. Linker CA, Ries CA. Damon LE, Rugo HS, Wolf JL (1993) Autologous bone marrow transplantation for acute myeloid leukemia using busulfan plus etoposide as a preparative regimen. Blood 81:311-318
69. Lipshultz SE, Lipsitz SR, Mone SM, Goorin AM, Sallan SE, Sanders SP, Orav JE, Gelber RD, Colan SD (1995) Female sex and higher drug dose as risk factors for late cardiotoxic effects of doxorubicin therapy for childhood cancer. N Engl J Med 332:1738-1743
70. McLeod HL, Relling MV, Crom WR, Silverstein K, Groom S, Rodman JH, Rivera GK, Crist WM, Evans WE (1992) Disposition of antineoplastic agents in the very young child. Br J Cancer 66 [Suppl XVIII]:S23-S29
71. Mahmoud HH, Hurwitz CA, Roberts MW, Santana VM, Ribeiro RC, Krance RA (1993) Tretinoin toxicity in children with acute promyelocytic leukaemia. Lancet 342:1394-1395
72. Mayer RJ, Davis RB, Schiffer CA, Berg DT, Powell BL, Schulman P, Omura GA, Moore JO, McIntyre RO, Frei E (1994) Intensive postremission chemotherapy in adults with acute myeloid leukemia. N Engl J Med 331:896-903
73. Meng-er H, Yu-Chen Y, Shu-Rong C, Jin-ren C, Jia-Xiang L, Lin Z, Long-jun G, Zhen-yi W (1988) Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. Blood 72:567-572
74. Menke T, Pröbsting B, Schultze-Westhoff P, Ritter J, Boos J (1994) Clinical relevance of the influence of etoposide on Ara-CTP formation in leukemic blasts cells. In: Büchner T, Hiddemann W, Wörmann B, Schellong G, Ritter J (eds) Acute leukemias IV: prognostic factors. Springer-Verlag, Berlin Heidelberg New York pp 270-272
75. Michel G, Gluckman E, Biaise D, Esperou-Bourdeau H, Vernant JP, Kuentz M, Bordigoni P, Milpied N, Rubie H, Thuret I, Troussard X, Frappaz D, Herve P, Plouvier E, Gratecos N, Bernaudin F, Lioure B, Bergeron C, Jouet JP, Gardembas-Pain M, Belanger C, Gouvernet J, Perrimond H, Maranichi D (1992) Improvement in outcome for children receiving allogeneic bone marrow transplantation in first remission of acute myeloid leukemia: a report from the Groupe d'Etude des Greffes de Moelle Osseuse. J Clin Oncol 10:1865-1869
76. Michel G, Gluckman E, Esperou-Bourdeau H, Reiffers J, Pico JL, Bordigoni P, Thuret I, Biaise D, Bernaudin F, Jouet JP, Lemerle S, Rubie H, Milpied N, Vannier JP, Demeocq F, Troussard X, Gratecos N, Plouvier E, Bergeron C, Gardembas M, Gouvernet J, Maraninchi D (1994) Allogeneic bone marrow transplantation for children with acute myeloblastic leukemia in first complete remission: impact of conditioning regimen without total-body irradiation - A report from the Societe Francaise de Greffe de Moelle. J Clin Oncol 12:1217-1222
77. Morra E, Lazzarino M, Brusamolino E, Pagnucco G, Castagnola C, Bernasconi P, Orlandi E, Corso A, Santagostino A, Bernasconi C (1993) The role of systemic high-dose cytarabine in the treatment of central nervous system leukemia. Cancer 72:439-445
78. Nesbit ME, Buckley JD, Feig SA, Anderson JR, Lampkin B, Bernstein ID, Kim TH, Piomelli S, Kersey JH, Coccia PF, O'Reilly RC, August C, Thomas DE, Hammond DG (1994) Chemotherapy for induction of remission of childhood acute myeloid leukemia followed by marrow transplantation or multiagent chemotherapy: a report from the Childrens Cancer Group. J Clin Oncol 12:127-135
79. Nishikawa A, Nakamura Y, Nobori U, Aoki T, Higashino H, Matsui T, Kobayashi Y, Yamshita M, Unishi G (1987) Acute monocytic leukemia in children. Response to VP16-213 as a single agent. Cancer 60:2146-2149
80. Nucifora G, Larson RA, Rowley JD (1993) Persistence of the 8;21 translocation in patients with acute myeloid leukemia type M2 in long-term remission. Blood 82:712-715
81. Odom LF, Gordon EM (1984) Acute monoblastic leukemia in infancy and early childhood: successful treatment with an epipodophyllotoxin. Blood 64:875-882
82. Onega JJ, Olive T, Diaz-de-Heredia C, Bastida P, Massuet LI, Giralt J (1995) High-lights of ANLL therapy in Spain. Med Pediatr Oncol 25:271
83. Plunkett W, Jacoboni S, Estey E, Danhauser L, Liliemark JO, Keating MJ (1985) Pharmacologically directed ara-C therapy for refractory leukemia. Semin Oncol 12 [Suppl 3]:20-30
84. Preisler H, Davis RB, Kirshner J, Dupre E, Richards F, Hoagland CH, Kopel S, Levy RN, Carey R, Schulman P, Gottlieb AJ, McIntyre RO (1987) Comparison of three remission induction regimens and two postinduction strategies for the treatment of acute nonlymphocytic leukemia: a Cancer and Leukemia Group B study. Blood 69:1441-1449
85. Pui C-H (1995) Childhood leukemias. N Engl J Med 332:1618-1630
86. Pui C-H, Raimondi SC, Head DR, Schell MJ, Rivera GK, Mirro J, Crist WM, Behm FG (1991) Characterization of childhood acute leukemia with multiple myeloid and lymphoid markers at diagnosis and at relapse. Blood 78:1327-1337
87. Pui C-H, Kane JR, Crist WM (1995) Biology and treatment of infant leukemias. Leukemia 9:762-769
88. Rai KR, Holland JF, Glidewell OJ, Weinberg V, Brunner K, Obrecht JP, Preisler HD, Nawabi IW, Prager D, Carey RW, Cooper RM, Haurani F, Hutchison JL, Silver RT, Falkson G, Wiernik P, Hoagland CH, Bloomfield CD, James WG, Gottlieb A, Ramanan SV, Blom J, Nissen NI, Bank A, Ellison RR, Kung F, Henry P, McIntyre RO, Kaan SK (1981) Treatment of acute myelocytic leukemia: a study by Cancer and Leukemia Group B. Blood 58:1203-1212
89. Ravindranath Y, Steuber PC, Krischer J, Civin CI, Ducore J, Vega R, Pitel P, Inoue S, Bleher E, Sexauer C, Hutter J, Vietti T (1991) High-dose cytarabine for intensification of early therapy of childhood acute myeloid leukemia: a Pediatric Oncology Group Study. J Clin Oncol 9:572-580
90. Ravindranath Y, Abella E, Krischer JP, Wiley J, Inoue S, Harris M, Chauvenet A, Alvarado CS, Dubowy R, Ritchey AK, Land V, Steuber CP, Weinstein H (1992) Acute myeloid leukemia (AML) in Down's syndrome is highly responsive to chemotherapy: experience on Pediatric Oncology Group AML Study 8498. Blood 80:2210-2214
91. Ravindranath Y, Yeager AM, Chang MN, Steuber CP, Krischer J, Graham-Pole J, Carroli A. Inoue S, Camitta B, Weinstein HJ (1996) Autologous bone marrow transplantation versus intensive chemotherapy for acute myeloid leukemia in childhood. N Engl J Med 334:1428-1434
92. Reid JM, Pendergrass TW, Krailo MD, Hammond DG, Ames MM (1990) Plasma pharmacokinetics and cerebrospinal fluid concentrations of idarubicin and idarubicinol in pediatrie leukemia patients: a Childrens Cancer Study Group Report. Cancer Res 50:6525-6528
93. Ritter J, Roos N (1995) Special aspects related to invasive fungal infections in children with cancer. Baillieres Clin Infect Dis 2:179-204
94. Ritter J, Creutzig U, Henze G, Jürgens H, Bode U, Prindull G, Schellong G (1987) Hochdosiertes ARA-C in Kombination mit Mitoxantron bei der Therapie der AML im Kindesalter. Erste Ergebnisse der AML-Rezidivstudie BFM-85. Onkologie 10:24-27
95. Ritter J, Vormoor J, Creutzig U, Schellong G (1989) Prognostic significance of Auer rods in childhood acute myelogenous leukemia: results of the studies AML-BFM-78 and -83. Med Pediatr Oncol 17:202-209
96. Ritter J, Creutzig U, Schellong G (1992) Treatment results of three consecutive German childhood AML trials: BFM-78, -83, and -87. Leukemia 6 [Suppl 2]:59-62
97. Robison LL, Nesbit ME, Sather HN, Level C, Shahidi N, Kennedy A, Hammond D (1984) Down syndrome and acute leukemia in children: a 10-year retrospective survey from Childrens Cancer Study Group. J Pediatr 105:235-242
98. Rustum YM, Raymakers RAP (1992) 1-β-arabinofuranosyl-cytosine in therapy of leukemia: preclinical and clinical overview. Pharmacol Ther 56:307-321
99. Sackmann-Muriel F, Fernandez-Barbieri MA, Santarelli MT, Matus-Ridley M, Rosso A, Negri-Aranguren P, Cerutti I, Gomel M, Kvicala R (1993) Results of treatment with an intensive combination induction regimen containing idarubicin in children with acute myeloblastic leukemia: preliminary report of the Argentine Group for Treatment of Acute Leukemia. Semin Oncol 20:34-38
100. Santana VM, Hurwitz CA, Blakley RL, Crom WR, Luo X, Roberts MW, Ribeiro R, Mahmoud H, Krance RA (1994) Complete hematologic remissions induced by 2-chlorodeoxyadenosine in children with newly diagnosed acute myeloid leukemia. Blood 84:1237-1242
101. Shaw PJ, Bergin ME, Burgess MA, Pozza LD, Kellie SJ, Rowell G, Stevens MM, Webster BH, Bradstock KF (1994) Childhood acute myeloid leukemia: outcome in a single center using chemotherapy and consolidation with busulfan/cyclophosphamide for bone marrow transplantation. J Clin Oncol 12:2138-2145
102. Silber JH, Jakacki RI, Larsen RL, Goldwein JW, Barber G (1993) Increased risk of cardiac dysfunction after anthracyclines in girls. Med Pediatr Oncol 21:477-479
103. Smith MA, Rubinstein L, Ungerleider RS (1994) Therapy-related acute myeloid leukemia following treatment with epipodophyllotoxins: estimating the risks. Med Pediatr Oncol 23:86-98
104. Steuber PC, Civin C, Krischer J, Culbert S, Ragab A, Ruyman FB, Ravindranath Y, Leventhal B, Wilkinson R, Vietti TJ (1991) A comparison of induction and maintenance therapy for acute nonlymphocytic leukemia in childhood: results of a Pediatric Oncology Group Study. J Clin Oncol 9:247-258
105. Stevens RF (1995) Results of the MRC AML 10 trial in children. Med Pediatr Oncol 25:272
106. Stevens RF, Hann IM, Wheatley K, Gray R (1992) Intensive chemotherapy with or without additional bone marrow transplantation in paediatric AML: progress report on the MRC AML 10 trial. Leukemia 6 [Suppl 2]:55-58
107. Tallmann MS, Andersen J, Schiffer CA, Appelbaum FR, Feusner JE, Woods WG. Ogden A, Weinstein H, Shepherd L, Rowe JM, Wiernik PH (1995) Phase III randomized study of all-trans retinoic acid (ATRA) vs daunorubicin (D) and cytosine arabinoside (A) as induction therapy and ATRA vs observation as maintenance therapy for patients with previously untreated acute promyelocytic leukemia (APL). Blood 86 [Suppl 1]:125a
108. Taub JW, Matherly LH, Stout ML, Buck SA, Gurney JG, Ravindranath Y (1996) Enhanced metabolism of 1-β-D-arabinofuranosylcytosine in Down syndrome cells: a contributing factor to the superior event free survival of Down syndrome children with acute myeloid leukemia. Blood 87:3395-3403
109. Tiedemann K, Waters KD, Tauro GP, Tucker D, Ekert H (1993) Results of intensive therapy in childhood acute myeloid leukemia, incorporating high-dose melphalan and autologous bone marrow transplantation in first complete remission. Blood 82:3730-3738
110. von-Hoff DD, Rozencweig M, Layard M, Slavik M, Muggia FM (1977) Daunomycin-induced cardiotoxicity in children and adults: a review of 110 cases. Am J Med 62:200-208
111. Vormoor J, Ritter J, Creutzig U, Schellong G (1989) Inzidenz und prognostische Bedeutung von Auerstäbchen bei Kindern mit akuter myeloischer Leukämie in den Studien AML-BFM-78 und -83. Klin Pädiatr 201:227-231
112. Vormoor J, Ritter J, Creutzig U, Boos J, Heyen P, Ludwig W-D, Harbott J, Löffler H, Schellong G (1992) Acute myelogenous leukaemia in children under 2 years - experiences of the West German AML studies BFM-78. -83 and -87. Br J Cancer 66 [Suppl XVIII]:S63-S67
113. Vormoor J, Lapidot T, Pflumio F, Risdon G, Patterson B, Broxmeyer HE, Dick JE (1994) Immature human cord blood progenitors engraft and proliferate to high levels in severe combined immunodeficient mice. Blood 83:2489-2497
114. Vormoor J, Ritter J, Jürgens H, Dick JE (1995) Significance of the SCID mouse models for the study of normal and leukemic human hemopoiesis and gene therapy. Onkologie 18:434-438
115. Vose JM, Armitage JO (1995) Clinical applications of hematopoietic growth factors. J Clin Oncol 13:1023-1035
116. Warrell RP, Frankel SR, Miller WH. Scheinberg DA, Itri LM, Hittelman WN, Vyas R, Andreeff M, Tafuri A, Jabukowski A, Gabrilove J, Gordon MS, Dimitrovsky E (1991) Differentiation therapy of acute promyelocytic leukemia with tretinoin (all-trans-retinoic acid). N Engl J Med 324:1385-1393
117. Weinstein HJ, Mayer RJ, Rosenthal DS, Coral FS, Camitta BM, Gelber RD (1983) Chemotherapy for acute myelogenous leukemia in children and adults: VAPA update. Blood 62:315-319
118. Wells RJ, Woods WG, Lampkin BC, Nesbit ME, Lee JW, Buckley JD, Versteeg C, Hammond DG (1993) Impact of high-dose cytarabine and asparaginase intensification on childhood acute myeloid leukemia: a report from the Childrens Cancer Group. J Clin Oncol 11:538-545
119. Wells RJ, Woods WG, Buckley JD, Odom LF, Benjamin D, Bernstein I, Betcher D, Feig S, Kim T, Ruymann F, Smithson W, Srivastava A, Tannous R, Buckley CM, Whitt K, Wolff L, Lampkin BC (1994) Treatment of newly diagnosed children and adolescents with acute myeloid leukemia: a Childrens' Cancer Group Study. J Clin Oncol 12:2367-2377
120. Wiernik PH, Banks PLC, Case DC, Arlin ZA, Periman PO, Todd MB, Ritch PS, Enck RE, Weitberg AB (1992) Cytarabine plus idarubicin or daunorubicin as induction and consolidation therapy for previously untreated adult patients with acute myeloid leukemia. Blood 79:313-319
121. Wingard JR, Plotnick LP, Freemer CS, Zahurak M, Piantadosi S, Miller DF, Vriesendorp HM, Yeager AM, Santos GW (1992) Growth in children after bone marrow transplantation: busulphan plus cyclophosphamide versus cyclophosphamide plus total body irradiation. Blood 79:1068-1073
122. Witherspoon RP, Fisher LD, Schoch G, Martin P, Sullivan KM, Sanders J, Deeg JH, Doney K, Thomas D, Storb R, Thomas DE (1989) Secondary cancers after bone marrow transplantation for leukemia or aplastic anemia. N Engl J Med 321:784-789
123. Wolff SN, Herzig RH, Fay JW, Phillips GL, Lazarus HM, Flexner JM, Stein RS, Greer JP, Cooper B, Herzig GP (1989) High-dose cytarabine and daunorubicin as consolidation therapy for acute myeloid leukemia in first remission: long-term follow-up and results. J Clin Oncol 7:1260-1267
124. Woods WG, Kobrinsky N, Buckley J, Neudorf S, Sanders J, Miller L, Barnard D, Benjamin D, DeSwarte J, Kalousek D, Shina D, Hammond GD, Lange BJ (1993) Intensively timed induction therapy followed by autologous or allogeneic bone marrow transplantation for children with acute myeloid leukemia or myelodysplastic syndrome: a Childrens Cancer Group Pilot Study. J Clin Oncol 11:1448-1457
125. Woods WG, Kobrinsky N, Buckley J, Lee JW, Sanders J, Neudorf S, Gold S, Barnad D, DeSwarte J, Dusenbery K, Kalousek D, Arthur D, Lange BJ (1995) Timed sequential induction therapy improves postremission outcome in pediatric acute myeloid leukemia (AML). Med Pediatr Oncol 25:271
126. Wörmann B, Könemann S, Grove D, Toepker S, Heinecke A, Sauerland C, Büchner T, Hiddemann W, Terstappen LWMM (1995) Minimal residual disease in adults with de novo AML. Blood 86 [Suppl 1]:331a
127. Yates J, Glidewell O, Wiernik P, Cooper RM, Steinberg D, Dosik H, Levy R, Hoagland C, Henry P, Gottlieb A, Cornell C, Berenberg J, Hutchison LJ, Raich P, Nissen N, Ellison RR, Frelick R, James WG, Falkson G, Silver RT, Haurani F, Green M, Henderson E, Leone L, Holland JF (1982) Cytosine arabinoside with daunorubicin or adriamycin for therapy of acute myelocytic leukemia: a CALGB study. Blood 60:454-462
128. Yeager AM, Rowley SD, Kaizer H, Santos GW (1990) Ex vivo chemopurging of autologous bone marrow with 4-hydroperoxycyclophosphamide to eliminate occult leukemic cells. Am J Pediatr Hematol Oncol 12:245-256
129. Zipursky A, Thorner P, Harven Ed, Christensen H, Doyle J (1994) Myelodysplasia and acute megakaryoblastic leukemia in Down's syndrome. Leuk Res 18:163-171
130. Zittoun RA, Mandelli F, Willemze R, Witte Td, Labar B, Resegotti L, Leoni F, Damasio E, Visani G, Papa G, Caronia F, Hayat M, Stryckmans P, Rotoli B, Leoni P, Peetermann ME, Dardenne M, Vegna ML, Petti MC, Solbu G, Suciu S (1995) Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia. N Engl J Med 332:217-223
131. Bishop JF, Matthews JP, Young GA, Szer J, Gillett A, Joshua D, Bradstock K, Enno A, Wolf Mm, Fox R, Cobcroft R, Herrmann R, van der Weyden M, Lowenthal RM, Page F, Garson OM, Juneja S (1996) A randomized study of high-dose cytarabine in induction in acute myeloid leukemia. Blood 87:1710-1717